日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Personalized Therapy Selection by Integration of Molecular Cancer Classification by the 92-Gene Assay and Tumor Profiling in Patients With Cancer of Unknown Primary

通过整合 92 基因检测的分子癌症分类和肿瘤分析,为原发灶不明的癌症患者提供个性化治疗选择

Harry E Fuentes Bayne, Pashtoon M Kasi, Li Ma, Lowell L Hart, Jenna Wong, David R Spigel, Catherine A Schnabel, James A Reeves, Thorvardur R Halfdanarson, Kai Treuner, F Anthony Greco

Immunohistochemical basis for FAP as a candidate theranostic target across a broad range of cholangiocarcinoma subtypes

FAP 作为多种胆管癌亚型的候选治疗诊断靶点的免疫组织化学基础

Laura C Jorgenson, Michael S Torbenson, Thorvardur R Halfdanarson, Lionel A Kankeu Fonkoua, Nguyen H Tran, Lewis R Roberts, Rory L Smoot, Ajit H Goenka, Scott M Thompson

Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma

KRAS 野生型胰腺导管腺癌的分子特征和治疗机会

Aakash Desai, Alexander H Xiao, Daheui Choi, Merih D Toruner, Daniel Walden, Thorvardur R Halfdanarson, Steven Alberts, Robert R McWilliams, Amit Mahipal, Daniel Ahn, Hani Babiker, Gulnaz Stybayeva, Alexander Revzin, Sani Kizilbash, Alex Adjei, Tanios Bekaii-Saab, Aaron S Mansfield, Ryan M Carr, Wen

Understanding Suboptimal Response to Immune Checkpoint Inhibitors

了解对免疫检查点抑制剂的次优反应

Mojun Zhu, Henan Zhang, Katrina S Pedersen, Nathan R Foster, Brandy L Jaszewski, Xin Liu, Jacob B Hirdler, Zesheng An, Tanios S Bekaii-Saab, Thorvardur R Halfdanarson, Patrick M Boland, Yiyi Yan, Joleen H Hubbard, Wen Wee Ma, Harry H Yoon, Alexander Revzin, Martin E Fernandez-Zapico, Michael J Overm

Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors

胰腺内分泌肿瘤新治疗策略的分子标记

Judith A Gilbert, Laura J Adhikari, Ricardo V Lloyd, Thorvardur R Halfdanarson, Michael H Muders, Matthew M Ames